Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Non-cash Items (2017 - 2024)

Historic Non-cash Items for UroGen Pharma (URGN) over the last 8 years, with Q4 2024 value amounting to $1.1 million.

  • UroGen Pharma's Non-cash Items fell 7871.76% to $1.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.1 million, marking a year-over-year decrease of 7871.76%. This contributed to the annual value of $1.1 million for FY2024, which is 7871.76% down from last year.
  • Per UroGen Pharma's latest filing, its Non-cash Items stood at $1.1 million for Q4 2024, which was down 7871.76% from $5.1 million recorded in Q4 2023.
  • UroGen Pharma's Non-cash Items' 5-year high stood at $13.5 million during Q4 2020, with a 5-year trough of $1.1 million in Q4 2024.
  • Its 5-year average for Non-cash Items is $4.8 million, with a median of $2.1 million in 2021.
  • As far as peak fluctuations go, UroGen Pharma's Non-cash Items crashed by 8407.63% in 2021, and later skyrocketed by 16862.96% in 2023.
  • UroGen Pharma's Non-cash Items (Quarter) stood at $13.5 million in 2020, then tumbled by 84.08% to $2.1 million in 2021, then dropped by 11.15% to $1.9 million in 2022, then surged by 168.63% to $5.1 million in 2023, then tumbled by 78.72% to $1.1 million in 2024.
  • Its last three reported values are $1.1 million in Q4 2024, $5.1 million for Q4 2023, and $1.9 million during Q4 2022.